洞察菌素在动脉样硬化中的机制作用
Hayder M Al-Kuraishy1, Ghassan M Sulaiman2, Hamdoon A Mohammed3
1Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Current atherosclerosis reports
|March 20, 2025
概括
一种抗炎药物 - - 科尔奇辛,通过向血管炎症和氧化应激,有望减少动脉样硬化 (AS) 的严重程度. 需要进行进一步的研究,以充分阐明它对抗AS进展的保护机制.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 炎症生物学 炎症生物学
背景情况:
- 动脉样硬化 (AS) 是一个日益严重的全球健康问题,目前还没有特定的药物治疗方法.
- 阿斯的发病包括内皮功能障碍,由氧化低密度脂蛋白 (oxLDL) 引发的巨细胞介导炎症和白细胞透.
- 炎症过程和分子信号是AS斑块发育,侵蚀,破裂和血栓形成的核心.
研究的目的:
- 审查和讨论胆固醇在预防动脉样硬化 (AS) 的发展和进展方面的保护机制.
- 探索菌素的抗炎性质如何减轻AS病变的发生.
- 为AS提供潜在治疗策略的见解.
主要方法:
- 对研究科尔奇辛对动脉样硬化的影响的文献综述.
- 分析研究研究的分子和细胞机制背后的科尔奇辛的作用.
- 综合与AS炎症,氧化应激和自相关的发现.
主要成果:
- 科尔奇辛在众多研究中表明,它可以减少AS的严重程度.
- 科尔奇辛对AS的有益作用的确切机制尚未完全明确,但涉及向关键的炎症途径.
- 有证据表明,素会影响内皮功能障碍,巨细胞激活和炎症媒介释放.
结论:
- 胆固醇抑制血管炎症,氧化应激和血小板聚合,从而减少AS的发展和进展.
- 菌素对自的调节也可能有助于其对动脉样硬化的保护作用.
- 针对炎症,使用诸如素之类的药物,为管理AS及其并发症提供了潜在的治疗途径.
更多相关视频
相关概念视频
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:38Inflammation
52.1K
Overview
52.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
585
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
585
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
431
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
431
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
441
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
441